Management of hepatocellular obstruction: guidelines of the European Society of Gastroenterology (ES

Recently, global medical institutions and the public health system have continued to advance service capacity building to provide stronger guarantees for public health. Nonprofit organizations recommend the use of multi-purpose all-metal braces (FCSEMS) when using benign gallbladder blockage caused by post-treatment gallbladder removal. When braces are located away from the major hepatic veins or non-patients refuse to repeatedly perform ERCPs, consideration may be given to FCSEMS.

In this case, temporary insertion of FCSEMS (6-12 months) can be used to treat cavity-associated narrowing of the gallbladder. ESGE recommends the use of single-bladed uncovered SEMss (USEMss) for bile secretion outflow only in secondary to primary sclerosing cholangitis (secondary to primary cholangitis) secondary complications. Diagnosis of distal malignant bile duct strictures with unconfirmed etiology for unknown causes requires a comprehensive understanding and assessment of the anatomical structure, pathological changes, and clinical performance of the bile duct.

A comprehensive analysis of the above can lead to clinically practical and practical diagnostic conclusions that provide effective treatments and precautions for patients. ESGE recommends the use of intracellular ultrasound, subcutaneous or epithelial gallbladder surgery (PBD) as a primary pressure relief treatment for ulcerative, peripheral MBOs. 9: ESGE recommends ERCP as a replacement for Percutaneous Transhepatic Biliary Drainage (PTBD) for Hilar Malignant Obstruction.

10: ESGE recommends Palliative Drainage of Malignant Hilar Strictures by means of ERCP for Bismuth Types I-II. The combination of Bismuth III-IV, ERCP or ERCP with Endoscopic Ultrasound-Guided Biliary Drainage (EUS-BD) is better than Primary P TBD. Supplemental drainage may be required in some cases with PTBD.

According to the recommendations of ESGE, drainage of more than 50% of the drainage, ideally 70% or higher, is required for the verification of acceptable alternative liver transplants in malignant Bismuth II-IV-blocked liver tissue. By using the multi-modal method (EUS-BD/PTBD, if necessary, as a complementary method to ERCP), PTBD may in some cases be used to obtain additional, greater than 50%, acceptable alternative liver transplant drainage. In this way, PTBD may in some cases be used to obtain an additional, greater than 50%, acceptable alternative liver transplant discharge, thus in some cases it may be used to obtain an additional, greater than 50%, acceptable alternative liver transplant discharge, thus in some cases it may be used to obtain an additional, greater than 50%, acceptable alternative liver transplant discharge, thus in some cases it may be used to obtain an additional, greater than 50%, acceptable alternative liver transplant discharge.

Alternative liver transplant drainage, which may in some cases be used to obtain an additional, greater than 50%, acceptable alternative liver transplant drainage, which may in some cases be used to obtain an additional, greater than 50%, acceptable alternative liver transplant drainage, which may in some cases be used to obtain an additional, greater than 50%, acceptable alternative liver transplant drainage12: ESGE recommends the use of plastic syringes or USEMSs for malicious liver blockage. EGSE recommends the use of plastic syringes or USEMSs where the best withdrawal strategy is not defined. It should be noted that the above content is based on international public research findings and is for reference in HealthCop and does not constitute a clinical recommendation.

If you have any health questions, please consult professional medical personnel.